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F a s t  F a c ts
• People with HIV and latent TB infection are at much higher risk for progressing to active TB disease than people 
with latent TB infection alone.
• All people newly diagnosed with HIV should be tested for TB infection. If they are infected with TB bacteria, 
immediate treatment can prevent them from progressing to TB disease.
Tuberculosis, or TB, is caused by the bacterium Mycobacterium tuberculosis, which can be present as either latent 
infection or active disease. Latent TB infection means that TB bacteria are living in the body but not causing any 
symptoms. People w ith latent TB infection are not sick, do not have symptoms, and cannot spread the disease.
TB disease means that the bacteria are multiplying and are destroying body tissues; if not diagnosed and treated 
properly, it can be fatal. People w ith TB disease are sick, do have symptoms, and can spread the disease. Only TB disease 
is infectious; latent TB infection is not. TB disease of the lungs or airways can be spread from person to person through
the air when a person w ith TB disease coughs, sneezes, speaks, or sings.
A ll people new ly diagnosed w ith  HIV should be tested fo r TB in fection  as soon as possible. People liv ing  
w ith  HIV and at ongo ing  risk fo r TB exposure should be tested annually. The risk for exposure to TB is the same 
for everyone: being in close contact w ith someone w ith infectious TB disease. This risk increases for people who 
are homeless or injection drug users, or those living or working in settings such as jails, health care facilities, drug- 
treatment units, or homeless shelters.
TB infection can be detected by a skin test or a blood test. If the test is positive, additional tests such as sputum tests 
and x-rays are needed to determine whether the infection has progressed to TB disease.
People with HIV and latent TB infection need treatment as soon as possible to prevent them from developing TB 
disease. People w ith HIV who have latent TB infection are much more likely to progress to TB disease than people 
w ithout HIV. TB outbreaks can rapidly expand in patient groups infected w ith HIV. Treatment for latent TB infection 
usually is a single drug (most commonly isoniazid) taken for 9 months. A new combination regimen of isoniazid and 
rifapentine taken weekly for 12 weeks as directly observed therapy (DOT) is recommended for some people. (In DOT, 
health care workers meet w ith TB patients individually to watch them take each dose of TB medicine.) People w ith HIV
and TB disease must take several drugs for 6 to 9 months to treat their TB.
Unfortunately, some people w ith HIV do not know they are infected w ith TB. Similarly, one in five people with 
TB disease are unaware of their HIV status, although HIV status reporting for people w ith TB is improving. CDC 
recommends that anyone who has TB disease, is suspected of having TB disease, or is a contact o f a TB patient, be 
tested for HIV.
T h e  N u m b e r s
• In 2009, 1.1 million people in the United States were living w ith HIV, 18% of whom did not know they were 
infected.
• The rate of new TB disease diagnoses in 2011 was 3.4 per 100,000 population (10,528 cases), the lowest since 
reporting began in 1953.
• In 2011, 82% of patients w ith TB disease knew their HIV status.
• Among 8,683 people with TB disease who had a documented HIV test result in 2011, 6% were coinfected w ith HIV.
• In 2006, 12% (769 of 6,533) of TB patients w ith reported HIV test results had HIV, but accounted for 32% (131 of 412) 
of those who died during treatment and 51% (32 of 63) of those who received a TB diagnosis postmortem.
• In 2011, the rate of incident TB cases among foreign-born people in the United States was 12 times as great as 
among US-born people. Among US-born racial and ethnic groups, non-Hispanic blacks had a rate six times that of 
non-Hispanic whites.
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P r e v e n t i o n  C h a l l e n g e s
M ultid rug -res is tan t TB (MDR TB) is TB that is resistant to at least two of the best anti-TB drugs— isoniazid and 
rifampin. MDR TB is hard to treat and can be fatal. People w ith HIV are at greater risk of dying of MDR TB than those 
w ithout HIV. The percentage of MDR TB cases in the United States has remained steady since 1998; in 2011, among 
all reported TB cases in the United States, 1.3% were characterized as primary MDR TB (defined as no previous 
history o f TB disease). Extensively drug-resistant TB is a rare type of MDR TB that is resistant not only to isoniazid and 
rifampin, but also any fluoroquinolone and at least one of three injectable second-line drugs. It is extremely hard to 
treat, and the remaining treatment options are less effective.
To prevent the continued emergence of drug-resistant strains, treatment for TB must be improved, not only in the 
United States but worldwide. Although a person w ith drug-resistant TB can transmit the resistant bacteria directly to 
others, resistance primarily develops when a TB patient is not treated w ith the right drugs or does not take the drugs 
properly. The most effective way to ensure that patients finish their treatment is DOT, and its use must be expanded.
Possible drug in teractions can interfere w ith treatment. Treatment w ith the right drugs is important for HIV 
patients. Recommendations for treating TB in adults with HIV are, w ith a few exceptions, the same as those for adult 
TB patients who are not HIV infected. However, managing HIV-related TB is complex, and people w ith HIV and TB 
should seek care from a health care provider or providers with expertise in the management of both diseases.
Lack o f awareness o f TB or HIV status can prevent adequate treatment. Anyone who is newly diagnosed w ith HIV 
or TB should be tested for coinfection. People need to know their status. W ithout treatment, each disease increases 
the severity of the other. TB disease is, in fact, an AIDS-defining condition. Worldwide, TB is a leading cause of death 
among people living with HIV.
W h a t  CD C Is D o in g
CDC and its domestic and international partners, including the National TB Controllers 
Association, Stop TB USA, the global Stop TB Partnership, the TB Trials Consortium, and 
the TB Epidemiologic Studies Consortium, are taking many steps to prevent the further 
spread of TB and to reduce the overall burden of the disease. Efforts include
• Assessing new TB diagnostic techniques.
• Developing new treatment regimens.
• Increasing the capacity of health professionals to provide adequate patient care by 
offering training and promoting evidence-based guidelines.
• Continuing to address and support global TB control, since foreign-born people 
account for more than half o f TB cases in the United States.
TB control is an exercise in vigilance. The goal of controlling and eventually eliminating 
TB requires a focused, continual effort to meet the prevention and treatment needs of 
people most at risk, including those who have HIV. The strategy of preventing and 
treating TB in people w ith HIV is therefore essential to achieving the goal of TB elimination 
in the United States.
For more information, see the Bibliography at 
(http://www.cdc.gov/hiv/resources/factsheets/hivtb.htm).
Additional Resources
CDC-INFO
1-800-CDC-INFO (232-4636) 
cdcinfo@cdc.gov 
Get answers to questions 
and find HIV testing sites.
CDC HIV Website
www.cdc.gov/hiv
National HIV and STD Testing 
Resources
http://hivtest.cdc.gov
CDC National Prevention 
Information Network (NPIN)
1-800-458-5231 
www.cdcnpin.org 
Technical assistance and 
resources.
Act Against AIDS
http://www.cdc.gov/
actagainstaids
AIDSinfo
1-800-448-0440 
www.aidsinfo.nih.gov 
Treatment and clinical trials.
AIDS.gov
www.aids.gov 
Comprehensive government 
HIV resources.
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